Evaluation of the effects of novel anti-amyloid immunotherapies in real-world clinical practice

A key feature of Alzheimer’s disease is accumulation of amyloid in the brain. Recently, anti-amyloid immunotherapies that effectively clear amyloid have been developed.

This marks the start of new era in treatment of Alzheimer’s disease, but also brings entirely new challenges like: How can we predict which patients will respond most best to treatment? How can we predict the individual risk of developing serious side effects (brain edema/hemorrhages)?

What are the effects of treatment on the brain, beyond removal of amyloid?To answer these questions, we aim to launch a national multifaceted Swedish initiative to investigate anti-amyloid therapies in the real world.

Upon the anticipated approval of these treatments in 2024, a collaboration will be formed to characterize patients in detail using imaging, plasma and cerebrospinal fluid biomarkers.

We will uncover i) predictors for treatment response, ii) predictors for side effects, and iii) brain changes related to amyloid removal.

We leverage complementary world-leading expertise in Alzheimer´s disease biomarker and imaging studies to fill important knowledge gaps.The initiative aims to equip clinicians with tools for refining treatment decisions, mitigating the risk of adverse effects, and optimizing resource allocation.

Given the potential side-effects and high societal costs of these novel treatments, the study’s findings will offer invaluable insights for enhancing both patient care and resource management.